Clinical trial of isophosphamide (NSC-109724)--results and side effects.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D002986:Clinical Trials as Topic; D003498:Cyclic P-Oxides / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003556:Cystitis / Q000139:chemically induced; D004341:Drug Evaluation; D005021:Ethylamines / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006029:Glycosuria / Q000139:chemically induced; D006452:Hemoglobinometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010078:Oxazines / Q000009:adverse effects / Q000627:therapeutic use*; D012075:Remission, Spontaneous
D000970:Antineoplastic Agents; D003498:Cyclic P-Oxides; D005021:Ethylamines; D010078:Oxazines; D003520:Cyclophosphamide